Skip to main content

Table 2 Patient outcomes

From: Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity

 

Entire cohort

Primary disease

Recurrent disease

Metastatic disease

p-value

Overall survival

1-year rate, %

89.2

93.7

83.5

88.9

0.42

3-year rate, %

63.4

70.5

52.2

44.4

0.16

Progression free survival

1-year rate, %

37.3

50.1

38

12.5

0.05

3-year rate, %

18.1

26.8

19

0

0.07

Local control

1-year rate, %

83.5

83.8

82.8

85.2

0.99

3-year rate, %

65.4

71.7

57.6

0.12